# Nuritas

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuritas

- Industry: Biotechnology
- Headquarters: Dublin, Ireland
- Website: www.nuritas.com/
- Total disclosed funding: $115M
- Latest round: Series C (Dec 20, 2024)
- Investors on record: 15

## About

Based in Ireland, Nuritas Ltd. specializes in biotechnology by developing cell-signaling peptides derived from natural sources to enhance health and wellness across various industries.Nuritas Ltd., founded in 2014, is headquartered in Dublin, Ireland. The company focuses on biotechnology, specifically developing bioactive peptides for dietary supplements and cosmetics. Nora K is the CEO and founder, who has a background in health sciences. Nuritas has completed a total of 10 funding deals, with the most recent being a SERIES C round on December 20, 2024, where they raised USD 42.00 mn led by M&G Investments and supported by investors like ECBF Management GmbH, Grosvenor, and McWin. The total amount raised by the company stands at USD 42.00 mn.Nuritas specializes in precision, cell-signaling peptide ingredients sourced from natural materials. Their leading products, PeptiYouth™ and PeptiStrong™, enhance the effectiveness of dietary supplements, functional foods, medical foods, and cosmetics. Utilizing advanced AI technology, Nuritas identifies and unlocks bioactive peptides, with a library cataloging over 8 million peptides, each with specific functionalities. The company primarily markets its products in North America, Europe, and Asia, serving a broad client base that includes manufacturers and health-conscious consumers.In the most recent year, Nuritas reported a revenue of USD 1,172,928.70. The company generates income through partnerships in the health, nutrition, and cosmetics sectors, supplying proprietary peptide ingredients such as PeptiYouth™ and PeptiStrong™ to manufacturers. Their business model includes collaboration agreements and licensing fees tailored to meet the specific needs of clients, ensuring competitive pricing while maintaining product integrity.In December 2024, Nuritas, Ltd. raised USD 42.00 mn in SERIES C funding, led by M&G Investments, to further develop its AI platform for discovering and creating a range of holistic products. This funding will support the launch of new products targeting health and wellness challenges, aiming for market expansion into additional regions within Europe and Asia by 2025.

## Funding rounds

- Series C, Dec 20, 2024, $42M — Grosvenor, M&G, ECBF, McWin
- Series B, Nov 4, 2021, $50M — Cultivian Sandbox Ventures, Grupo Nutresa, CJ Group, Clay Capital, Vertex Holdings, Veronorte, Cleveland Avenue, Wheatsheaf Group, ECBF
- Series A, Dec 19, 2017, $18M — Cultivian Sandbox Ventures, Clay Capital, Enterprise Ireland, Amici Ventures Limited
- Series A, Mar 30, 2016, $1.8M — Clay Capital, Acdeng Property Limited
- Seed, Sep 16, 2015, $3.3M — Clay Capital

## Investors

- Clay Capital (https://capitalatlas.ai/funds/clay-capital) — Seed, Series A, Series B
- Acdeng Property Limited — Series A
- Cultivian Sandbox Ventures (https://capitalatlas.ai/funds/cultivian-sandbox-ventures) — Series A, Series B
- Enterprise Ireland (https://capitalatlas.ai/funds/enterprise-ireland) — Series A
- Amici Ventures Limited — Series A
- Grupo Nutresa — Series B
- CJ Group — Series B
- Vertex Holdings (https://capitalatlas.ai/funds/vertex-holdings) — Series B
- Veronorte (https://capitalatlas.ai/funds/veronorte) — Series B
- Cleveland Avenue (https://capitalatlas.ai/funds/cleveland-avenue) — Series B
- Wheatsheaf Group (https://capitalatlas.ai/funds/wheatsheaf-group) — Series B
- ECBF (https://capitalatlas.ai/funds/ecbf) — Series B, Series C
- Grosvenor — Series C
- M&G (https://capitalatlas.ai/funds/m-g) — Series C
- McWin (https://capitalatlas.ai/funds/mcwin) — Series C